Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

A Case of Skin Eruption Occurred after Switching Formulation of Quetiapine Fumarate

Quetiapine Fumarate의 제형 변경 후 발생한 피부 발진 1예

  • Kwon, Yong-Seok (Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University) ;
  • Lim, Se-Won (Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University)
  • 권용석 (성균관대학교 의과대학 강북삼성병원 정신과학교실) ;
  • 임세원 (성균관대학교 의과대학 강북삼성병원 정신과학교실)
  • Published : 2009.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Adverse drug reactions are very common in clinical practice, and skin is one of the most frequent organs for adverse drug reactions. We report a case of a 71-year-old male patient who developed skin eruptions after switching formulation of quetiapine immediate release(IR) to quetiapine extended release(XR). He had been taking quetiapine IR(400mg/day) for treatment of manic episode which was developed one year ago. The patient showed great improvement of symptoms after taking quetiapine IR for about one year, thus dosage of medication was reduced to 50mg/day on the average. Unfortunately dose reduction has tended to worsen symptoms, so dose of quetiapine was increased again to 200mg/day with formulation changes to XR. Two days after he took new formulation, erythematous papules were occurred over his anterior neck and ventral side of left wrist. As he stopped quetiapine XR, the skin lesions gradually subsided. And he was successfully treated with readministration of quetiapine IR without any skin lesions.

Keywords

References

  1. Bigby M, Stern R. Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. J Am Acad Dermatol 1985;12:866-876. https://doi.org/10.1016/S0190-9622(85)70110-7
  2. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001;53:357-379.
  3. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998;51:703-708. https://doi.org/10.1016/S0895-4356(98)00041-9
  4. Merk HF, Hertl M. Immunologic mhanisms of cutaneous dug ractions. Semin Cutan Med Surg 1996;15 228-235. https://doi.org/10.1016/S1085-5629(96)80035-6
  5. GlaxoSmithKline. Lamictal. PRESCRIBING INFORMATION. http://us.gsk.com/products/assets/us-lamictal.pdf
  6. Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapineinduced toxic hepatitis with skin rash. J Psychopharmacol 2005;19:107. https://doi.org/10.1177/0269881105047287
  7. Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001;321:156-158. https://doi.org/10.1097/00000441-200102000-00008
  8. Stanislav SW, Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine. Ann Pharmacother 1999;33:1008-1009. https://doi.org/10.1345/aph.19038
  9. Calabrese JR. A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360. https://doi.org/10.1176/appi.ajp.162.7.1351
  10. Thase ME. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study(the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609. https://doi.org/10.1097/01.jcp.0000248603.76231.b7
  11. Kahn RS. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832-842. https://doi.org/10.4088/JCP.v68n0603
  12. Vieta E. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934. https://doi.org/10.1185/030079905X46340
  13. Cutler AJ. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-539. https://doi.org/10.4088/JCP.08m04592
  14. Nemeroff CB. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63:5-11.
  15. Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000;101:119-124. https://doi.org/10.1034/j.1600-0447.2000.90061.x
  16. Figueroa C. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:199-204. https://doi.org/10.1016/j.pnpbp.2008.09.026
  17. Colom F. Clinical factors associated to treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-555. https://doi.org/10.4088/JCP.v61n0802
  18. Osterberg L. Adherence to medication. N Engl J Med 2005;353:487-497. https://doi.org/10.1056/NEJMra050100
  19. Ascher-Svanum H. Medication adherence and longterm functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-460. https://doi.org/10.4088/JCP.v67n0317
  20. Pirmohamed M. Adverse drug reactions. BMJ 1998;316:1295-1298. https://doi.org/10.1136/bmj.316.7140.1295
  21. Romano A. Diagnostic evaluation of delayed hypersensitivity to systematically administered drugs. Allergy 1999;54:23-27. https://doi.org/10.1111/j.1398-9995.1999.tb04744.x
  22. Roychowdhury S. Mechanisms of Drug-induced Delayedtype Hypersensitivity Reactions in the Skin. The AAPS Journal 2005;7:834-846. https://doi.org/10.1208/aapsj070480
  23. Wolkenstein P. Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf 1995;13:56-68. https://doi.org/10.2165/00002018-199513010-00007
  24. Aronson JK. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003;327:1222-1225. https://doi.org/10.1136/bmj.327.7425.1222
  25. Edwards IR. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259. https://doi.org/10.1016/S0140-6736(00)02799-9
  26. Ganesan S. Switching from other antipsychotics to oncedaily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24:21-32. https://doi.org/10.1185/030079908X253384
  27. Seroquel XR. PRESCRIBING INFORMATION. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf
  28. Siepmann F. Polymer blends for controlled release coatings. J Control Release 2008;125:1-15. https://doi.org/10.1016/j.jconrel.2007.09.012
  29. Frohoff-Hulsmann MA. Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and hydroxypropyl methyl cellulose as coating material for diffusion pellets I: Drug release rates from coated pellets. Int J Pharm 1999;177:69-82. https://doi.org/10.1016/S0378-5173(98)00327-5
  30. Hsu ER. The effects of plasticizers and titanium dioxide on the properties of poly(vinyl alcohol) coatings. Pharm Dev Technol 2001;6:277-284. https://doi.org/10.1081/PDT-100002204